Concurrent mucosal leishmaniasis and pulmonary tuberculosis.
Escobar
M A
MA
Department of Medicine, University of Connecticut Health Center, Farmington 06030, USA.
Saravia
N G
NG
Weigle
K A
KA
D000818:Animals; D000904:Antibiotics, Antitubercular / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000627:therapeutic use*; D000075202:Contraindications; D004359:Drug Therapy, Combination; D006801:Humans; D007111:Immunity, Cellular; D007538:Isoniazid / Q000627:therapeutic use*; D007891:Leishmania / Q000187:drug effects; D007897:Leishmaniasis, Mucocutaneous / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008536:Meglumine; D000077485:Meglumine Antimoniate; D008875:Middle Aged; D009942:Organometallic Compounds; D011718:Pyrazinamide / Q000627:therapeutic use*; D012293:Rifampin / Q000627:therapeutic use*; D013183:Sputum / Q000382:microbiology; D013307:Streptomycin / Q000627:therapeutic use*; D014397:Tuberculosis, Pulmonary / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*
D000904:Antibiotics, Antitubercular; D000995:Antitubercular Agents; D009942:Organometallic Compounds; D011718:Pyrazinamide; D008536:Meglumine; D000077485:Meglumine Antimoniate; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin